StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

Stock analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Sunday. The firm set a “hold” rating on the stock.

Other equities analysts have also recently issued research reports about the stock. JMP Securities reiterated a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th. HC Wainwright raised their price target on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Trading Down 2.3 %

DBV Technologies stock opened at $4.13 on Friday. The stock has a 50-day moving average price of $3.75 and a two-hundred day moving average price of $3.87. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $9.40. The company has a market capitalization of $84.85 million, a PE ratio of -0.92 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.90) by $1.10. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The firm had revenue of $1.07 million for the quarter, compared to the consensus estimate of $1.17 million. As a group, analysts predict that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.